Top Markets
Coin of the day
Elevation Oncology, Inc. Elevation Oncology, Inc.

Elevation Oncology, Inc.

ELEV
Rank in Stocks #29358
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company... Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Share Price
$0.365
Last synced: 2025-08-01
Market Cap
$21.54M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Elevation Oncology, Inc. (ELEV)

Category

EPS for Elevation Oncology, Inc. (ELEV)
EPS as of 2026 TTM: 0
According to Elevation Oncology, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Elevation Oncology, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$2.98 -
AU
- -
CH